STOCK TITAN
  1. Home
  2. Sec-filings
  3. INKT
  4. [Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

INKT Form 4: Director Barbara Ryan Receives 3,225-Share Option Grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MiNK Therapeutics director Barbara Ryan received a stock option grant on 09/09/2025. The option gives the right to buy 3,225 shares of common stock at an exercise price of $15.36 per share, is exercisable beginning 09/09/2025, and expires 09/09/2035. The option vests in full on the one-year anniversary of the grant date if the reporting person continues to serve on the board. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/11/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine director equity award that clarifies compensation timing and vesting.

The filing documents a standard director stock option grant to a board member, specifying grant date, exercise price, quantity, vesting condition and a ten-year term. The one-year cliff vesting aligns the award with continued board service. Because the disclosure is limited to a single option award of 3,225 shares, the filing appears procedural and focused on aligning director incentives with shareholder value rather than signaling a governance change.

TL;DR: Small, time-limited equity grant; not a market-moving transaction based on disclosed size.

The Form 4 reports an option exercisable at $15.36 for 3,225 shares, exercisable from 09/09/2025 and expiring 09/09/2035. The disclosure is precise on terms and ownership following the grant. There is no sales or disposition reported and no derivative holdings beyond this option. Without additional material transactions or related-party changes disclosed, the impact on capitalization and dilution appears limited from the information provided.

Insider Ryan Barbara
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 3,225 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 3,225 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ryan Barbara
(Last) (First) (Middle)
149 FIFTH AVENUE, SUITE 500
(Street)
NEW YORK NY 10010
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $15.36 09/09/2025 A 3,225 (1) 09/09/2035 Common Stock 3,225 $0 3,225 D
Explanation of Responses:
1. The option vests in full on the one-year anniversary of the date of grant, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.
By: /s/ Christine Klaskin, Attorney-in-Fact 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What security was reported on the INKT Form 4?

The filing reports a stock option (right to buy common stock) for MiNK Therapeutics (INKT).

How many shares are underlying the option and what is the exercise price?

The option covers 3,225 shares with an exercise price of $15.36 per share.

When is the option exercisable and when does it expire?

The option is exercisable beginning 09/09/2025 and expires on 09/09/2035.

What is the vesting condition for the option reported by Barbara Ryan?

The option vests in full on the one-year anniversary of the grant date, contingent on continued board service.

Who filed the Form 4 and when was it signed?

The Form 4 was filed by one reporting person and the filing was signed by an attorney-in-fact on 09/11/2025.